SUMMARY
Objective. To evaluate the effectiveness of cabergoline treatment in reducing prolactin levels and tumor size in patients with microprolactinoma. Material and Methods. The study included 59 patients diagnosed with microprolactinoma who were treated with cabergoline for 12 months. Clinical and anthropometric parameters were assessed along with prolactin levels at baseline, 3, 6, and 12 months. Tumor size was evaluated via CT at 6 and 12 months. Results. Mean prolactin levels decreased from 147.5 to 5.3 ng/mL over 12 months (p<0.001). The frequency of normoprolactinemia reached 98.3%. Tumor size reduced from 5.1 mm to 1.9 mm; complete tumor regression was observed in 18.6% of patients. Conclusion. Cabergoline is highly effective in treating microprolactinoma, significantly reducing both prolactin levels and tumor volume.
Keywords: microprolactinoma, pituitary adenoma, cabergoline, prolactinemia, treatment

---

REFERENCES

1. Melmed S, Kaiser UB, Lopes MB, et al. Clinical Biology of the Pituitary Adenoma // Endocr Rev. 2022;43(6):1003-1037. doi: 10.1210/endrev/bnac010.
2. Mirzəzadə V.A., Qurbanov Y.Z., Əzizov V.Ə., Alimetov S.N. və başq. Endokrin Xəstəlikləri. Bakı, Azərdiab nəşriyyati, 2022, 512 s.
3. Гарднер Д., Шобек Д. Базисная клиническая эндокринология. Книга 2 / Перев. с англ.- Москва: Издательство БИНОМ, 2017, 696 с.
4. Мелмед Ш., Полонски К., Ларсен П.Р., Кроненберг Г.М. Эндокринология по Уильямсу. Репродуктивная эндокринология. Перевод с английского 2-е издание на русском языке под редакцией академика РАН И.И. Дедова,
5. World Health Organization. Report of the Fifth Meeting of the South- East Asia Regional Technical Advisory Group and first meeting of Sexual Reproductive Health Technical subcommittee towards reduction of maternal mortality and stillbirths in the context of universal health coverage New Delhi India, 25-27 November, 2019. https://iris.who.int/handle/10665/331817.
6. World Health Organization. Report of the Sixth Meeting of the South-East Asia Regional Technical Advisory Group (‎SEAR-TAG)‎ and SRHR Technical Subcommittee (‎SEA/SRH/2)‎. https://iris.who.int/handle/10665/343596.
7. World Health Organization. Virtual Expert Group Meeting to Review Competency-Based Pre-Service Curriculum and Training Resources for Safe Abortion. 19 - 21 May 2021, New Delhi, India. https://cdn.who.int/media/docs/default-source/country-profiles/mca/report-safeabortion.pdf?sfvrsn=de397efa_3.
8. World Health Organization. Regional capacity building for policy dialogue on Sexual and Reproductive Health and Rights, 15 June - 30 November 2021. https://cdn.who.int/media/docs/default-source/country-profiles/mca/report-capacity-building-policy-dialogue-srhr.pdf?sfvrsn=30dc6a95_3.
9. Pan American Health Organization, World Health Organization. Sexual and Reproductive Health. https://www.paho.org/en/topics/sexual-and-reproductive-health
10. Dzialach L, Sobolewska J, Zak Z, Respondek W, Witek P. Prolactin-secreting pituitary adenomas: male-specific differences in pathogenesis, clinical presentation and treatment // Front Endocrinol (Lausanne). 2024;15:1338345. doi: 10.3389/fendo.2024.1338345.
11. Fukuhara N, Nishiyama M, Iwasaki Y. Update in Pathogenesis, Diagnosis, and Therapy of Prolactinoma // Cancers (Basel). 2022 Jul 24;14(15):3604.13 p.
12. Ворожцова И.Н., Павленко О.А., Лукьянёнок П.И., Коновалова Н.А. Пролактинома: этиологические, диагностические и терапевтические аспекты // Современные проблемы науки и образования. - 2016. - № 4, https://science-education.ru/ru/article/view?id=24886.
13. Исмаилов Д.Б. Хирургическое лечение пролактинсекретирующих аденом гипофиза: Автореферат Диссертации на соискание ученой степени кандидата медицинских наук. М., 2021, 24 с.
14. Fukuhara N, Nishiyama M, Iwasaki Y. Update in Pathogenesis, Diagnosis, and Therapy of Prolactinoma // Cancers (Basel). 2022 Jul 24;14(15):3604 doi: 10.3390/cancers14153604.
15. Chanson P, Maiter D. The epidemiology, diagnosis and treatment of Prolactinomas: The old and the new // Best Pract Res Clin Endocrinol Metab. 2019 Apr;33(2):101290. doi: 10.1016/j.beem.2019.101290.
16. Molitch, M.E. Diagnosis and Treatment of Pituitary Adenomas: A Review // JAMA J. Am. Med. Assoc. 2017, 317, 516-524. doi: 10.1001/jama.2016.19699.
17. Willacy H. Prolactinoma. https://patient.info/hormones/prolactinoma#
18. Khare S., Lila A.R., Patt H., Yerawar C. et al. Gender differences in macroprolactinomas: a single centre experience // Endocr Connect, 2016, 5 (1):20-27. doi: 10.1530/EC-15-0105.
19. Segu V.B. Prolactinoma Clinical Presentation. Updated: Feb 15, 2022. https://emedicine.medscape.com/article/124634-clinical.
20. Лакин Г.Ф. Биометрия. Издание третье, переработанное и дополненное. Москва «Высшая школа», 1980, 293 с.
21. EasyCalculation.com. Confidence Limits for Mean Calculator. https://www.easycalculation.com/statistics/confidence-limits-mean.php
22. Psyhol-ok Психологическая помощь. Назначение t-критерия Стьюдента. https://www.psychol-ok.ru/statistics/student/.
23. EPITOOLS. Calculate confidence limits for a sample proportion. https://epitools.ausvet.com.au/ciproportion.
24. Social Science Statistics. Easy Fisher Exact Test Calculator. https://www.socscistatistics.com/tests/fisher/default2.aspx.